{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:37:26Z","timestamp":1790890646591,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1053\/j.semdp.2017.11.003","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T16:07:53Z","timestamp":1517501273000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Drug induced pseudolymphoma"],"prefix":"10.1053","volume":"35","author":[{"given":"Cynthia M.","family":"Magro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianne H.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Neil","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/hupa.2003.4","article-title":"Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells","volume":"34","author":"Magro","year":"2003","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.path.2017.01.002","article-title":"Cutaneous Pseudolymphoma","volume":"10","author":"Mitteldorf","year":"2017","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0046-8177(96)90365-2","article-title":"Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis","volume":"27","author":"Magro","year":"1996","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1053\/j.semdp.2017.11.003_bib4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archderm.1992.01680200081011","article-title":"Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of S\u00e9zary syndrome","volume":"128","author":"D'Incan","year":"1992","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1053\/j.semdp.2017.11.003_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archderm.143.7.921","article-title":"Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones","volume":"143","author":"Guitart","year":"2007","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1053\/j.semdp.2017.11.003_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1056\/NEJM195603152541107","article-title":"Diphenylhydantoin sensitivity: report of fatal case with hepatitis and exfoliative dermatitis","volume":"254","author":"Gropper","year":"1956","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.semdp.2017.11.003_bib8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/archderm.1995.01690200063012","article-title":"Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia","volume":"131","author":"Crowson","year":"1995","journal-title":"Arch Dermatol"},{"issue":"2 Pt 2","key":"10.1053\/j.semdp.2017.11.003_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0190-9622(92)70195-L","article-title":"Generalized nodular cutaneous pseudolymphoma associated with phenytoin therapy. Use of T-cell receptor gene rearrangement in diagnosis and clinical review of cutaneous reactions to phenytoin","volume":"27","author":"Braddock","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1053\/j.semdp.2017.11.003_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archderm.128.1.121","article-title":"Generalized cutaneous B-cell pseudolymphoma induced by neuroleptics","volume":"128","author":"Luelmo Aguilar","year":"1992","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1053\/j.semdp.2017.11.003_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1600-0560.2006.00475.x","article-title":"Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response","volume":"33","author":"Breza","year":"2006","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib12","first-page":"308","article-title":"Jessner lymphocytic infiltrate as a side effect of bee venom immunotherapy","volume":"22","author":"Yalcin","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"10.1053\/j.semdp.2017.11.003_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2340\/00015555-1785","article-title":"Duloxetine-induced pseudolymphoma with features of lymphocytic infiltration of Jessner-Kanof","volume":"94","author":"Corazza","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bcp.12837","article-title":"Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus","volume":"81","author":"Guarneri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1191\/1352458505ms1130cr","article-title":"Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate","volume":"11","author":"Nolden","year":"2005","journal-title":"Mult Scler"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0536.2007.01087.x","article-title":"Lymphomatoid contact dermatitis to an exotic wood: a very harmful toilet seat","volume":"57","author":"Ezzedine","year":"2007","journal-title":"Contact Dermat"},{"issue":"3","key":"10.1053\/j.semdp.2017.11.003_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0536.2002.470308_10.x","article-title":"Lymphomatoid allergic contact dermatitis from para-phenylenediamine","volume":"47","author":"Calzavara-Pinton","year":"2002","journal-title":"Contact Dermat"},{"issue":"3","key":"10.1053\/j.semdp.2017.11.003_bib18","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2230.2003.01258.x","article-title":"Lymphomatoid contact dermatitis to para-tertyl-butyl phenol resin","volume":"28","author":"Evans","year":"2003","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1053\/j.semdp.2017.11.003_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0091-6749(98)70069-7","article-title":"Lymphomatoid contact dermatitis caused by isopropyl-diphenylenediamine: two cases","volume":"102","author":"Marli\u00e8re","year":"1998","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.path.2017.01.002","article-title":"Cutaneous pseudolymphoma","volume":"10","author":"Mitteldorf","year":"2017","journal-title":"Surg Pathol Clin"},{"issue":"6","key":"10.1053\/j.semdp.2017.11.003_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/17474086.2013.845000","article-title":"Cutaneous pseudolymphomas: inflammatory reactive proliferations","volume":"6","author":"Hussein","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1053\/j.semdp.2017.11.003_bib22","first-page":"445","article-title":"Cutaneous lymphoid hyperplasia: a case report and brief review of the literature","volume":"79","author":"Lackey","year":"2007","journal-title":"Cutis"},{"issue":"5","key":"10.1053\/j.semdp.2017.11.003_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.humpath.2005.02.012","article-title":"A review of 55 cases of cutaneous lymphoid hyperplasia: reassessment of the histopathologic findings leading to reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as pseudolymphomatous folliculitis","volume":"36","author":"Arai","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1053\/j.semdp.2017.11.003_bib24","series-title":"The Cutaneous Lymphoid Proliferation","author":"Magro","year":"2016"},{"issue":"1","key":"10.1053\/j.semdp.2017.11.003_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31818e52fe","article-title":"Primary cutaneous CD4+ small\/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers","volume":"33","author":"Rodr\u00edguez Pinilla","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0046-8177(99)90266-6","article-title":"Analysis of clonality of atypical cutaneous lymphoid infiltrates associated with drug therapy by PCR\/DGGE","volume":"30","author":"Brady","year":"1999","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2017.11.003_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1468-3083.2007.02540.x","article-title":"T- and B-cell clonally restricted pseudolymphoma in the setting of phytoestrogen therapy","volume":"22","author":"Magro","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00129039-200412000-00016","article-title":"Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay","volume":"12","author":"Chen","year":"2004","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7","key":"10.1053\/j.semdp.2017.11.003_bib29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/DAD.0000000000000692","article-title":"CD30 positive lymphomatoid angiocentric drug reactions: characterization of a series of 20 cases","volume":"39","author":"Magro","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"10.1053\/j.semdp.2017.11.003_bib30","doi-asserted-by":"crossref","DOI":"10.5070\/D32311037249","article-title":"Pityriasis lichenoides-like drug reaction: a clinical histopathologic study of 10 cases","author":"Magro","year":"2017","journal-title":"Dermatol Online J"},{"issue":"7","key":"10.1053\/j.semdp.2017.11.003_bib31","first-page":"743","article-title":"Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors","volume":"61","author":"Massay","year":"2012","journal-title":"West Indian Med J"},{"issue":"5","key":"10.1053\/j.semdp.2017.11.003_bib32","first-page":"769","article-title":"Revisiting cutaneous adverse reactions to pemetrexed","volume":"2","author":"Pi\u00e9rard-Franchimont","year":"2011","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib33","first-page":"235","article-title":"[Pityriasis-lichenoides-et-varioliformis-acuta-like drug exanthema caused by astemizole]","volume":"44","author":"Stosiek","year":"1993","journal-title":"Hautarzt"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000288","article-title":"Relapsing drug-induced hypersensitivity syndrome","volume":"16","author":"Tan","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1\u20133","key":"10.1053\/j.semdp.2017.11.003_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12026-012-8271-0","article-title":"Severe drug eruptions revisited","volume":"53","author":"Calbo","year":"2012","journal-title":"Immunol Res"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jdv.12130","article-title":"Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"28","author":"Barbaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"issue":"1","key":"10.1053\/j.semdp.2017.11.003_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/00015550410024094","article-title":"Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells","volume":"85","author":"Hashizume","year":"2005","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1053\/j.semdp.2017.11.003_bib39","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9308","key":"10.1053\/j.semdp.2017.11.003_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.semdp.2017.11.003_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.anndiagpath.2017.02.003","article-title":"Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome","volume":"28","author":"Nguyen","year":"2017","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1053\/j.semdp.2017.11.003_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.semdp.2017.11.003_bib43","article-title":"Predominant contribution of CD4 T cells to human herpesvirus 6 (HHV-6) load in the peripheral blood of patients with drug-induced hypersensitivity syndrome and persistent HHV-6 infection","author":"Miyagawa","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1053\/j.semdp.2017.11.003_bib44","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/his.13157","article-title":"Human herpesvirus 6 lymphadenitis in drug rash with eosinophilia and systemic symptoms syndrome: a lymphoma mimic","volume":"70","author":"Johnson","year":"2017","journal-title":"Histopathology"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib45","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2340\/00015555-2309","article-title":"CD30-positive cutaneous pseudolymphoma caused by tocilizumab in a patient with rheumatoid arthritis: case report and literature review","volume":"96","author":"Inoue","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1053\/j.semdp.2017.11.003_bib46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/DAD.0b013e31827a0c46","article-title":"Acute generalized exanthematous pustulosis with histopathologic findings of lymphomatoid drug reaction","volume":"35","author":"Llamas-Velasco","year":"2013","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0560.1998.tb01693.x","article-title":"The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity","volume":"25","author":"Magro","year":"1998","journal-title":"J Cutan Pathol"},{"issue":"Suppl 1","key":"10.1053\/j.semdp.2017.11.003_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0560.2010.01518.x","article-title":"Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction","volume":"37","author":"Magro","year":"2010","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1053\/j.semdp.2017.11.003_bib49","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0046-8177(99)90216-2","article-title":"Atypical pigmentary purpura: a clinical, histopathologic, and genotypic study","volume":"30","author":"Crowson","year":"1999","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib50","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.jaad.2014.05.042","article-title":"Erythrodermic CD8+ pseudolymphoma during infliximab treatment in a patient with psoriasis: use of cyclosporine as a rescue therapy","volume":"71","author":"Safa","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1053\/j.semdp.2017.11.003_bib51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MCG.0000000000000513","article-title":"Cutaneous pseudolymphoma in a patient With Crohn's disease under infliximab: first report","volume":"50","author":"Carvalhana","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00129039-200412000-00016","article-title":"Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay","volume":"12","author":"Chen","year":"2004","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"10.1053\/j.semdp.2017.11.003_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0560.2007.00813.x","article-title":"Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates","volume":"35","author":"Plaza","year":"2008","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1744-313X.2011.01061.x","article-title":"HLA alleles and drug hypersensitivity reactions","volume":"39","author":"Profaizer","year":"2012","journal-title":"Int J Immunogenet"},{"issue":"2","key":"10.1053\/j.semdp.2017.11.003_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/dmpt-2016-0025","article-title":"An update on HLA alleles associated with adverse drug reactions","volume":"32","author":"Fricke-Galindo","year":"2017","journal-title":"Drug Metab Pers Ther"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257017301259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257017301259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:19:33Z","timestamp":1719785973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257017301259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0740257017301259"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2017.11.003","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug induced pseudolymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}